title: Biochemical and behavioral studies following subchronic administration of GABA uptake inhibitors in mice.
abstract: N-(4,4-Diphenyl-3-butenyl) nipecotic acid (SKF(R)-89976A) and N-(4,4-diphenyl-3-butenyl) guvacine (SKF 100330A) are potent inhibitors of the uptake of GABA and have anticonvulsant properties. In the present study, the effects of these compounds on several behavioral and biochemical measures were determined, following subchronic administration. Administration of SKF(R)-89976A (8.9 mg/kg) for 14 days caused a small but significant reduction in its potency to protect against pentylenetetrazole-induced seizures, whereas treatment with SKF 100330A (13.6 mg/kg) had no significant effect. The percentage of animals rendered cataleptic by administration of either GABA uptake inhibitor was reduced by treatment for as few as 4 days and treatment with SKF(R)-89976A for 14 days resulted in a 4-fold increase in the CD50 for induction of catalepsy. The binding of [3H]GABAA and [3H]GABAB in membranes from the forebrain of the mouse were not influenced by treatment with drug nor was synaptosomal uptake of [3H]GABA. Likewise, the binding of [3H]sulpiride in striatal membranes of the mouse was unaffected by repeated exposures to SKF(R)-89976A. These results demonstrate that prolonged administration of GABA uptake inhibitors produced only a small reduction in anticonvulsant potency, whereas liability to side-effects, as demonstrated by the reduction in catalepsy, was substantially reduced.
authors.affiliation: Nova Pharmaceutical Corporation, Baltimore, MD 21224-6522.
authors.forename: E W
authors.initials: EW
authors.lastname: Karbon
authors.forename: S J
authors.initials: SJ
authors.lastname: Enna
authors.forename: J W
authors.initials: JW
authors.lastname: Ferkany
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage*; D002375:Catalepsy / Q000139:chemically induced / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D015394:Molecular Structure; D009539:Nicotinic Acids / Q000008:administration & dosage*; D009557:Nipecotic Acids / Q000008:administration & dosage*; D010433:Pentylenetetrazole; D011954:Receptors, Dopamine / Q000378:metabolism; D011963:Receptors, GABA-A / Q000378:metabolism; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
chemical_list: D000927:Anticonvulsants; D009539:Nicotinic Acids; D009557:Nipecotic Acids; D011954:Receptors, Dopamine; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; C045598:N-(4,4-diphenyl-3-butenyl)nipecotic acid; C045597:SK&F 100330-A; D010433:Pentylenetetrazole